Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

4SC Presents Summary of Biomarker and Patient Subgroup Analysis of Prognostic Factors

Published: Tuesday, October 01, 2013
Last Updated: Monday, September 30, 2013
Bookmark and Share
Further information about proposed role of biomarker ZFP64 in HCC tumour progression presented.

4SC AG has presented a detailed summary of results of a patient subgroup analysis of prognostic factors for overall survival and biomarkers in the Phase II SHELTER trial in advanced liver cancer (HCC).

The data will be presented in a poster presentation, 30 September 2013, from 2:00 PM - 4:30 PM (CEDT), at the ECCO 2013 (European Cancer Congress 2013) in Amsterdam). The poster will also be online at www.4sc.de/product-pipeline/publications-posters/resminostat when the session begins at 2:00 PM (CEDT).

As previously reported, the SHELTER trial investigated the HDAC inhibitor resminostat both as a monotherapy and in combination with the cancer drug sorafenib (Nexavar®) as a 2nd line treatment of advanced HCC patients that had progressed under 1st line sorafenib therapy.

In the study, the combination of resminostat and sorafenib achieved a median overall survival (OS) of 8.1 months. This constitutes an additional gain of almost 3 months compared to the expected median OS of 5.2 months after progression on 1st line sorafenib therapy (see data from the 1st line HCC SHORE trial with sorafenib).

4SC is currently in preparation of pivotal clinical development plans for resminostat in combination with sorafenib in advanced HCC.

Dr Bernd Hentsch, Chief Development Officer of 4SC AG; comments: 'The identification of a number of most crucial patient characteristics relevant for survival expectations will now be supportive to guide the setup for our planned pivotal clinical development program with resminostat in advanced HCC. Furthermore, in conjunction with the application of our potentially predictive ZFP64 biomarker 4SC aims at developing resminostat into a personalized cancer medicine for this indication.'

Summary of the results presented at ECCO 2013 in further detail:
1) Selected baseline characteristics correlate with overall survival of advanced HCC patients in the SHELTER study

4SC reports results from the analysis of HCC patient baseline characteristics that appear to have an impact on overall survival in advanced HCC patients of the SHELTER study, treated with either resminostat monotherapy or in combination with sorafenib (Nexavar®). In the monotherapy arm, an overall good performance status of the patients (ECOG 0) and pre-treatment with a local ablative therapy (transarterial chemoembolization, TACE) correlated with a longer survival outcome. In the combination therapy arm in addition to ECOG 0 also the absence of liver cirrhosis (Child-Pugh A) and the absence of vascular invasion of the liver tumour was identified to correlate with a prolonged overall survival.

Notably, in both treatment arms the time interval between end of 1st line sorafenib therapy and 2nd line treatment start in the SHELTER study ('drug holidays') had no influence on the median OS of SHELTER patients. These and other factors will be considered as important enrollment and stratification criteria for the currently planned pivotal Phase III studies with resminostat in combination with sorafenib as a novel treatment option for advanced HCC.

2) High baseline expression of ZFP64 correlates with prolonged survival in cancer patients treated with resminostat; pharmacodynamic activity of resminostat (i.e. down-regulation of ZFP64 gene expression) confirmed; proposed role of ZFP64 in tumour progression further elaborated
In the search for suitable biomarkers that allow monitoring the pharmacodynamic activity of resminostat 4SC identified a set of genes that showed a robust and reproducible regulation of expression levels in response to resminostat within hours after drug exposure in peripheral blood of cancer patients. One of these highly regulated genes is the DNA binding transcription factor 'zinc-finger protein 64' (ZFP64). According to the current model of ZFP64 activity, this biomarker is expected to play a role in HCC tumour progression by promoting processes of liver inflammation and tumour progression in a dual way by (i) co-activation of NF-kB-mediated pro-inflammatory TLR signaling, and (ii) by co-activating the pro-tumourigenic Notch1 pathway. ZFP64 levels in peripheral blood samples of HCC patients can be conveniently determined by quantitative PCR technology. ZFP64 blood levels were rapidly reduced approx. 5-fold in comparison to baseline levels within 2-5 hours after drug intake, presumably reflecting a similar response at the patients' tumour site, also suggested by similar results obtained in vitro in a variety of cancer cell lines of different tumour origins.

Moreover, baseline expression of ZFP64 in HCC patients before the start of treatment proved to correlate in a statistically significant manner (p=0.04) with the achieved clinical outcome, i.e. higher baseline expression was indicative of a longer overall survival than lower baseline expression of ZFP64. High ZFP64 expression was observed in about 2/3 of the patients, resulting in a doubling of the median OS value in comparison to the 1/3 of patients with low baseline ZFP64 expression.

Importantly, this observation in advanced HCC patients of the SHELTER study treated with either resminostat monotherapy or in combination with sorafenib (Nexavar®) was confirmed in a second Phase II study (SAPHIRE) in advanced Hodgkin Lymphoma (HL) patients treated with resminostat monotherapy, indicating a potential predictive character of this biomarker for response to resminostat treatment and suggesting a common underlying biological background in certain tumours that might be more responsive to treatment with resminostat.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Presents Results from Analysis of Biomarkers in Phase II SHELTER Trial in HCC
Oral presentation of detailed results at ILCA conference, 15 Sept. 2013, Washington D.C.
Friday, September 13, 2013
4SC Gives Update on the Clinical Development of its Lead Cancer Compound Resminostat
Data from completed Phase I part of SHORE study confirms the safety of the resminostat FOLFIRI combination and showing encouraging signs of clinical benefit
Thursday, May 30, 2013
4SC Reports Positive Data from Clinical Phase I trial with 4SC-205 in Cancer Patients
All primary objectives of the clinical study achieved.
Thursday, March 28, 2013
4SC to Present Biomarker Data for Cancer Drug Resminostat at EHA
Data from Phase II SAPHIRE trial in Hodgkin’s lymphoma presented at EHA meeting in Amsterdam.
Monday, June 18, 2012
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Grant to Fund Million Peaks Project
The European Research Council (ERC) has awarded a prestigious Advanced Grant to Prof. Peter Schoenmakers, Prof. Albert Polman and Prof. Huib Bakker, all three of whom work at the University of Amsterdam (UvA).
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!